Debbie brings over 25 years of biopharmaceutical experience in global clinical operations to K36 specializing in leading complex global clinical trials (Phase I-IV).   Debbie has deep expertise in CAR-T, BCMA, and TIL-based therapy clinical trials.

Most recently, Debbie served as Director of Clinical Operations, Vendor Management, and Data Management at Achilles Therapeutics, where she played a critical role in overseeing clinical trial execution, optimizing vendor partnerships, and ensuring data quality/integrity for next-generation TIL-based therapies in advanced solid tumors (melanoma and NSCLC).
 
Prior to Achilles Therapeutics, Debbie spent 19 years at Celgene/Bristol Myers Squibb where she led the end-to-end delivery of global registration trials for multiple blockbuster therapies (including Thalomid® (Thalidomide), Revlimid® (Lenalidomide), Pomalyst® (Pomalidomide) and led multiple change initiatives to improve operational delivery and efficiency including establishing Celgene’s risk management and centralized monitoring group.

Debbie is a passionate about patient awareness and access to novel treatment options via clinical trials.   With a proven track record of driving operational efficiency and executing high-impact clinical programs, Debbie is committed to advancing innovative therapies that improve patient outcomes.